{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:31:23Z","timestamp":1777905083280,"version":"3.51.4"},"reference-count":62,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"King Saud University, Riyadh, Saudi Arabia","award":["RSPD2024R907"],"award-info":[{"award-number":["RSPD2024R907"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: New multiple myeloma (MM) medications have revolutionized the treatment landscape, but they are also associated with a range of adverse events (AEs). This study aims to provide a comprehensive overview of AEs reported for four new MM medications: daratumumab, ixazomib, elotuzumab, and panobinostat. Methods: This study uses a descriptive retrospective approach to analyze the FDA Adverse Event Reporting System (FAERS) from 2015 to 2022. It includes variables like medication names, report details, patient demographics, adverse events, and reporter types. The initial dataset consists of over 3700 adverse events, which are categorized into 21 groups for clarity and comparison. Results: The FAERS database revealed 367,756 adverse events (AEs) associated with novel multiple myeloma drugs from 2015\u20132022. Ixazomib had the highest number of reported AEs with 206,243 reports, followed by daratumumab with 98,872 reports, then elotuzumab with 26,193 AEs. Ixazomib\u2019s AE reports increased dramatically over the study period, rising approximately 51-fold from 1183 in 2015 to 60,835 in 2022. Of the medications studied, ixazomib also recorded the highest number of deaths (24,206), followed by daratumumab (11,624), panobinostat (7227), and elotuzumab (3349). The majority of AEs occurred in patients aged 55\u201364 and 65\u201374 years. Conclusions: Ixazomib, a new MM medication, had the highest number of AEs reported. Also, it has the highest rate of reported deaths compared to other new MM medications. Clinicians should be aware of the potential AEs associated with this medication and further research is needed to understand the reasons for the high number of AEs and to develop mitigation strategies. More attention should also be paid to the safety of new multiple myeloma medications in younger patients.<\/jats:p>","DOI":"10.3390\/ph17070815","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T05:33:28Z","timestamp":1718948008000},"page":"815","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event Reporting System (FAERS) Databases from 2015 to 2022"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8504-3779","authenticated-orcid":false,"given":"Marwan A.","family":"Alrasheed","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2454, Riyadh 11451, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid A.","family":"Alamer","sequence":"additional","affiliation":[{"name":"Pharmacy Practice Department, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 34221, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mashael","family":"Albishi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2454, Riyadh 11451, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4852-1166","authenticated-orcid":false,"given":"Abdulrahman A.","family":"Alsuhibani","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, Qassim University, Buraidah 51452, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3792-4106","authenticated-orcid":false,"given":"Omar A.","family":"Almohammed","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2454, Riyadh 11451, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8519-3363","authenticated-orcid":false,"given":"Abdulrahman","family":"Alwhaibi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2454, Riyadh 11451, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah N.","family":"Almajed","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Centre, MBC 11, P.O. Box 3354, Riyadh 11211, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff J.","family":"Guo","sequence":"additional","affiliation":[{"name":"James L. Winkle College of Pharmacy, University of Cincinnati Academic Health Center, Cincinnati, OH 45267, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.bone.2008.01.027","article-title":"The pathogenesis of the bone disease of multiple myeloma","volume":"42","author":"Edwards","year":"2008","journal-title":"Bone"},{"key":"ref_2","first-page":"247","article-title":"Biological and molecular bases in the development of the pathogenic of the disease of multiple myeloma","volume":"60","year":"2019","journal-title":"Investig. Cl\u00ednica"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3343\/alm.2013.33.4.248","article-title":"Impact of Genetic Abnormalities on the Prognoses and Clinical Parameters of Patients with Multiple Myeloma","volume":"33","author":"Jekarl","year":"2013","journal-title":"Ann. Lab. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_6","unstructured":"(2023, September 28). Survival Rates for Multiple Myeloma. Available online: https:\/\/www.cancer.org\/cancer\/types\/multiple-myeloma\/detection-diagnosis-staging\/survival-rates.html."},{"key":"ref_7","first-page":"1444","article-title":"Immunomodulator drugs for the treatment of multiple myeloma","volume":"146","year":"2018","journal-title":"Rev. Med. Chil."},{"key":"ref_8","unstructured":"(2023, September 28). Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma|NEJM. Available online: https:\/\/www.nejm.org\/doi\/full\/10.1056\/nejmoa1606038."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1038\/bcj.2015.60","article-title":"Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib","volume":"5","author":"Kumar","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","article-title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: Final overall survival results from the phase 3 randomized ELOQUENT-2 study","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"Hungria","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11523-015-0413-6","article-title":"Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma","volume":"11","author":"Greig","year":"2016","journal-title":"Target Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_17","unstructured":"(2023, September 28). Ixazomib-Associated Cardiovascular Adverse Events in Multiple Myeloma: A Systematic Review and Meta-Analysis: Drug and Chemical Toxicology: Vol. 45, No 4. Available online: https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/01480545.2020.1835945."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-016-0284-z","article-title":"Elotuzumab for the treatment of multiple myeloma","volume":"9","author":"Wang","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/2040620715572295","article-title":"Daratumumab and its potential in the treatment of multiple myeloma: Overview of the preclinical and clinical development","volume":"6","author":"Phipps","year":"2015","journal-title":"Ther. Adv. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Palladini, G., Milani, P., Malavasi, F., and Merlini, G. (2021). Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis. Cells, 10.","DOI":"10.3390\/cells10030545"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2040620719894871","DOI":"10.1177\/2040620719894871","article-title":"Daratumumab in untreated newly diagnosed multiple myeloma","volume":"10","author":"Abdallah","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"ref_22","first-page":"70","article-title":"Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma","volume":"9","author":"Raedler","year":"2016","journal-title":"Am. Health Drug Benefits"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1080\/10428194.2018.1523398","article-title":"Ixazomib\u2014The first oral proteasome inhibitor","volume":"60","author":"Xie","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s40273-018-0644-3","article-title":"Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal","volume":"36","author":"Armoiry","year":"2018","journal-title":"PharmacoEconomics"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1080\/14656566.2018.1528229","article-title":"Ixazomib for the treatment of multiple myeloma","volume":"19","author":"Richardson","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/17474086.2018.1518129","article-title":"Ixazomib: A novel drug for multiple myeloma","volume":"11","author":"Zanwar","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"ref_27","first-page":"542","article-title":"Elotuzumab: The First Monoclonal Antibody for the Treatment of Multiple Myeloma","volume":"7","author":"Fancher","year":"2016","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_28","unstructured":"(2023, October 17). Emerging Combination Therapies for the Management of Multiple Myeloma: The Role of Elotuzumab\u2014PubMed, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/28744161\/."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1080\/14712598.2016.1221920","article-title":"Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma","volume":"16","author":"Lonial","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_30","unstructured":"(2023, October 17). Panobinostat\u2014An Overview|ScienceDirect Topics. Available online: https:\/\/www.sciencedirect.com\/topics\/medicine-and-dentistry\/panobinostat."},{"key":"ref_31","first-page":"296","article-title":"Panobinostat (Farydak): A Novel Option for the Treatment of Relapsed Or Relapsed and Refractory Multiple Myeloma","volume":"41","author":"Moore","year":"2016","journal-title":"Pharm. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.seminoncol.2023.03.006","article-title":"Outcomes with panobinostat in heavily pretreated multiple myeloma patients","volume":"50","author":"Pan","year":"2023","journal-title":"Semin. Oncol."},{"key":"ref_33","unstructured":"Inc SB (2023, October 17). Secura Bio Announces U.S. Withdrawal of FARYDAK\u00ae (panobinostat) NDA. Available online: https:\/\/www.prnewswire.com\/news-releases\/secura-bio-announces-us-withdrawal-of-farydak--panobinostat-nda-301434428.html."},{"key":"ref_34","unstructured":"Warren, K. (2023, January 01). Phase 1 Trial of Marizomib Alone and in Combination with Panobinostat for Children with Diffuse Intrinsic Pontine Glioma. clinicaltrials.gov; 2023 May. Report No.: NCT04341311, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04341311."},{"key":"ref_35","unstructured":"Wu, C.C. (2023, January 01). A Feasibility Study Examining the Use of Non-Invasive Focused Ultrasound (FUS) with Oral Panobinostat Administration in Children with Progressive Diffuse Midline Glioma (DMG). clinicaltrials.gov; 2022 Feb. Report No.: NCT04804709, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04804709."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Mainou, M., Bougioukas, K.I., Malandris, K., Liakos, A., Klonizakis, P., Avgerinos, I., Haidich, A.-B., and Tsapas, A. (2023). Reporting of adverse events of treatment interventions in multiple myeloma: An overview of systematic reviews. Ann. Hematol., 1\u201317.","DOI":"10.1007\/s00277-023-05517-7"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Pozzi, S., Bari, A., Pecherstorfer, M., and Vallet, S. (2021). Management of Adverse Events and Supportive Therapy in Relapsed\/Refractory Multiple Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13194978"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/s41375-018-0040-1","article-title":"Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network","volume":"32","author":"Ludwig","year":"2018","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Wang, J., Lv, C., Zhou, M., Xu, J.Y., Chen, B., and Wan, Y. (2022). Second Primary Malignancy Risk in Multiple Myeloma from 1975 to 2018. Cancers, 14.","DOI":"10.3390\/cancers14194919"},{"key":"ref_40","unstructured":"(2023, October 17). Research C for DE and Questions and Answers on FDA\u2019s Adverse Event Reporting System (FAERS). FDA. FDA; 2019, Available online: https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers."},{"key":"ref_41","unstructured":"(2023, October 11). Pharmacovigilance. Available online: https:\/\/www.who.int\/teams\/regulation-prequalification\/regulation-and-safety\/pharmacovigilance."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4103\/0975-1483.66802","article-title":"Pharmacovigilance: A Worldwide Master Key for Drug Safety Monitoring","volume":"2","author":"Jeetu","year":"2010","journal-title":"J. Young Pharm."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s40264-014-0225-0","article-title":"Stimulated Reporting: The Impact of US Food and Drug Administration-Issued Alerts on the Adverse Event Reporting System (FAERS)","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1177\/1078155220941937","article-title":"Differences in safety profiles of newly approved medications for multiple myeloma in real-world settings versus randomized controlled trials","volume":"27","author":"Borrelli","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_45","first-page":"218","article-title":"Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System","volume":"38","author":"Mina","year":"2021","journal-title":"Turk. J. Haematol. Off. J. Turk. Soc. Haematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e000773","DOI":"10.1136\/esmoopen-2020-000773","article-title":"Gender and sex disparity in cancer trials","volume":"5","author":"Lee","year":"2020","journal-title":"ESMO Open"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1200\/EDBK_175171","article-title":"Myeloma in Elderly Patients: When Less Is More and More Is More","volume":"37","author":"Rosko","year":"2017","journal-title":"Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Annu. Meet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.3390\/curroncol30060396","article-title":"Young Myeloma Patients: A Systematic Review of Manifestations and Outcomes","volume":"30","author":"Tanguay","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_49","first-page":"i","article-title":"Polypharmacy: A Global Risk Factor for Elderly People","volume":"6","author":"Dagli","year":"2014","journal-title":"J. Int. Oral. Health JIOH"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4065\/mcp.2009.0426","article-title":"Patterns of Multiple Myeloma During the Past 5 Decades: Stable Incidence Rates for All Age Groups in the Population but Rapidly Changing Age Distribution in the Clinic","volume":"85","author":"Turesson","year":"2010","journal-title":"Mayo Clin. Proc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2008.20.8983","article-title":"Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation","volume":"27","author":"Smith","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/asheducation-2018.1.88","article-title":"Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: Perspectives of a US hematologist and a geriatric hematologist","volume":"2018","author":"Wildes","year":"2018","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_53","unstructured":"Merck Sharp & Dohme Corp (2023, November 02). Withdrawal of Approval of New Drug Applications for VIOXX (Rofecoxib) Tablets and Suspension. Federal Register, Available online: https:\/\/www.federalregister.gov\/documents\/2022\/09\/13\/2022-19740\/merck-sharp-and-dohme-corp-withdrawal-of-approval-of-new-drug-applications-for-vioxx-rofecoxib."},{"key":"ref_54","unstructured":"(2023, November 02). Rosiglitazone: Recommended Withdrawal from Clinical Use. GOV.UK, Available online: https:\/\/www.gov.uk\/drug-safety-update\/rosiglitazone-recommended-withdrawal-from-clinical-use."},{"key":"ref_55","unstructured":"(2023, November 02). Commissioner O of the FDA Requests Removal of All Ranitidine Products (Zantac) from the Market. FDA. FDA; 2020, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-requests-removal-all-ranitidine-products-zantac-market."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/ejh.13435","article-title":"Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-\u03baB pathway activation","volume":"105","author":"Dash","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"9946","DOI":"10.1073\/pnas.1334037100","article-title":"Proteasome inhibitors disrupt the unfolded protein response in myeloma cells","volume":"100","author":"Lee","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: Back to the future","volume":"131","author":"Richardson","year":"2018","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Soekojo, C.Y., Ooi, M., de Mel, S., and Chng, W.J. (2020). Immunotherapy in Multiple Myeloma. Cells, 9.","DOI":"10.3390\/cells9030601"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.3389\/fimmu.2018.02551","article-title":"Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma","volume":"9","author":"Campbell","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Sch\u00fctt, J., N\u00e4gler, T., Schenk, T., and Brioli, A. (2021). Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic Modifications. Cancers, 13.","DOI":"10.3390\/cancers13164069"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-15-0530","article-title":"Panobinostat for the Treatment of Multiple Myeloma","volume":"21","author":"Laubach","year":"2015","journal-title":"Clin. Cancer Res."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/7\/815\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:02:10Z","timestamp":1760108530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/7\/815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":62,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["ph17070815"],"URL":"https:\/\/doi.org\/10.3390\/ph17070815","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]}}}